Mechanisms of D1/D2-like dopaminergic agonist, rotigotine, on lower urinary tract function in rat model of Parkinson’s disease
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mechanisms of D1/D2-like dopaminergic agonist, rotigotine, on lower urinary tract function in rat model of Parkinson’s disease
Authors
Keywords
-
Journal
Scientific Reports
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-03-16
DOI
10.1038/s41598-022-08612-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-term Outcome of Adenosine A2A Receptor Antagonist on Lower Urinary Tract Symptoms in Male Parkinson Disease Patients
- (2018) Takeya Kitta et al. CLINICAL NEUROPHARMACOLOGY
- New Frontiers of Basic Science Research in Neurogenic Lower Urinary Tract Dysfunction
- (2017) Minoru Miyazato et al. UROLOGIC CLINICS OF NORTH AMERICA
- Role of the Anterior Cingulate Cortex in the Control of Micturition Reflex in a Rat Model of Parkinson's Disease
- (2016) Takeya Kitta et al. JOURNAL OF UROLOGY
- Prevalence and treatment of LUTS in patients with Parkinson disease or multiple system atrophy
- (2016) Teruyuki Ogawa et al. Nature Reviews Urology
- Rotigotine is a potent agonist at dopamine D1receptors as well as at dopamine D2and D3receptors
- (2015) Martyn Wood et al. BRITISH JOURNAL OF PHARMACOLOGY
- Parkinson's disease
- (2015) Lorraine V Kalia et al. LANCET
- Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit
- (2013) Karen L. Eskow Jaunarajs et al. MOVEMENT DISORDERS
- Central nervous targets for the treatment of bladder dysfunction
- (2013) Naoki Yoshimura et al. NEUROUROLOGY AND URODYNAMICS
- Rotigotine Transdermal Patch in Parkinson’s Disease: A Systematic Review and Meta-Analysis
- (2013) Chang-Qing Zhou et al. PLoS One
- Steady-State Plasma Concentration Profile of Transdermal Rotigotine: An Integrated Analysis of Three, Open-Label, Randomized, Phase I Multiple Dose Studies
- (2012) Jan-Peer Elshoff et al. CLINICAL THERAPEUTICS
- Suppression of Bladder Overactivity by Adenosine A2A Receptor Antagonist in a Rat Model of Parkinson Disease
- (2012) Takeya Kitta et al. JOURNAL OF UROLOGY
- Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double-blind, randomized, placebo-controlled study (RECOVER)
- (2010) Claudia Trenkwalder et al. MOVEMENT DISORDERS
- From the cell to the clinic: A comparative review of the partial D2/D3 receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease
- (2010) Mark J. Millan PHARMACOLOGY & THERAPEUTICS
- Biphasic effect of apomorphine, an anti-parkinsonian drug, on bladder function in rats
- (2009) T. Uchiyama et al. NEUROSCIENCE
- GABAergic mechanism mediated via D1receptors in the rat periaqueductal gray participates in the micturition reflex: anin vivomicrodialysis study
- (2008) Takeya Kitta et al. EUROPEAN JOURNAL OF NEUROSCIENCE
- The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson’s disease
- (2008) Dieter Scheller et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More